Cascade Chemistry Selected to Produce API for COVID-19 Treatment

June 16, 2020
Pharmaceutical Technology Editors

The company has been selected to produce the active pharmaceutical ingredient for clinical trial supplies of RBT-9, an investigational therapy for the treatment of COVID-19 in patients at high risk of declining health due to age or comorbid conditions.

Cascade Chemistry, a contract research and manufacturing organization located in Eugene, OR, announced on June 16, 2020 that it has been selected to produce the active pharmaceutical ingredient (API) for clinical trial supplies of RBT-9, an investigational therapy for the treatment of COVID-19 in patients at high risk of declining health due to age or comorbid conditions.

Developed by Renibus Therapeutics, a clinical stage biotech company based in Southlake, TX, the API has been granted fast-track designation by FDA and has shown antiviral and immune-modulating activities in preclinical studies, a Cascade press release said. It is currently entering a Phase 2 trial.

“We welcomed the opportunity to join forces with Renibus to produce the API needed to speed RBT-9 into clinical trials for COVID-19,” said Jeremiah Marsden, PhD, president of Cascade Chemistry, in the press release.

“Cascade’s ability to move quickly to design, implement, and scale-up a comprehensive RBT-9 API manufacturing strategy has been one of the essential elements in our campaign to initiate clinical trials with minimal delay,” added Alvaro Guillem, CEO at Renibus Therapeutics, in the press release.

Source: Cascade